Literature DB >> 35592126

Expression of miR-4739 in Gastric cancer and its Relationship with Clinical Pathological Features of Patients.

Jiaxing Wei1, Jun Li1, Dong Geng1, Yiling Peng1, Bin Yang1, Huixian Wu1, Yun Zhou1.   

Abstract

Objective: To investigate the expression level of miR-4739 in gastric cancer (GC), analyze its diagnostic value in GC and the relationship with clinical pathological characteristics, and analyze its impact on the prognosis of patients.
Methods: A total of 96 patients with GC who underwent radical gastrectomy in our hospital from March 2017 to June 2021 were selected. GC tissues from all patients were collected, and normal tissues adjacent to cancer were collected as controls. The expression level of miR-4739 in tissues was detected, the relationship between miR-4739 and different pathological features was analyzed, and the diagnostic value of miR-4739 in GC was analyzed. All patients were followed up after the operation, and the survival time of the patients was set as from the day of the first operation to 1 d when the patients died or the follow-up ended.
Results: The relative expression level of miR-4739 in the GC tissue was (0.39 ± 0.06), lower than that in the paracancerous tissue (1.18 ± 0.19) (P < 0.05). The AUC of miR-4739 in the diagnosis of GC was 0.705. When the Youden index was 0.320 and the optimal cutoff value was 0.37, the sensitivity was 95.30% and the specificity was 36.70%. The expression level of miR-4739 in our patient was related to the differentiation degree, lymph node metastasis, tumor diameter, and TNM stage (P < 0.05). During the follow-up period, 26 of 96 patients died, and the survival rate was 72.92% (26/96). The median survival time was 29 months in the miR-4739 LE group, which was shorter than 39 months in the miR-4739 HE group (P < 0.05). Univariate analysis showed that age, degree of differentiation, lymph node metastasis, tumor diameter, TNM staging, and miR-4739 expression were all related to the prognosis of the patient (P < 0.05). Multivariate analysis showed that differentiation degree, lymph node metastasis, tumor diameter, TNM staging, and miR-4739 expression were all independent factors affecting the prognosis of the patients (P < 0.05).
Conclusion: The expression of miR-4739 in GC tissue was down-regulated, and its level was related to the degree of differentiation, lymph node metastasis, tumor diameter, and TNM stage. The expression level of miR-4739 has certain diagnostic value for patients with GC, and the prognosis of patients in LE group was worse than that in HE group.
Copyright © 2022 Wei, Li, Geng, Peng, Yang, Wu and Zhou.

Entities:  

Keywords:  clinical features; diagnostic value; gastric cancer; influencing factors; miR-4739; prognosis

Year:  2022        PMID: 35592126      PMCID: PMC9110967          DOI: 10.3389/fsurg.2022.897583

Source DB:  PubMed          Journal:  Front Surg        ISSN: 2296-875X


Introduction

Gastric cancer (GC) is a common gastrointestinal malignant tumor in clinic. In China, the incidence rate of GC in gastrointestinal malignant tumors ranks first, which seriously threatens the life quality of patients (1, 2). For the past few years, with the development of medical technology, the treatment of GC has made some progress, but the overall therapeutic effect and prognosis of patients with GC are still poor (3, 4). The occurrence of GC may be related to factors such as geographical, environmental, living habits, helicobacter pylori infection, precancerous lesions, heredity and genes, etc. Patients usually have no specific clinical manifestation at the initial stage of onset. Some patients have such symptoms as nausea and vomiting, and the diagnosis of early GC is difficult (5, 6). Up to now, the specific pathogenesis of GC is still unclear. At present, among patients diagnosed with GC in hospitals, about 90% of patients with advanced GC accompanied by different degrees of lymph node metastasis. The study showed that the early stage of GC treatment had a great influence on the therapeutic effect. The inpatients with GC had a late stage of disease, and the 5-year survival rate after radical gastrectomy in large general hospitals was about 35%. Among them, the average 5-year survival rate of patients with early GC is more than 90%, while the average 5-year survival rate of patients with advanced GC is poor, even less than 10% (2, 7). Therefore, in order to improve the prognosis of patients, clinical efforts have been made to find markers for early GC. Micro ribonucleic acid (miRNA) is an endogenous non-coding small RNA, which has been found to be extensively involved in the proliferation and migration of tumor cells (8, 9). The preliminary studies on miRNA mainly focus on the target genes and expression profiles of miRNA in different tissues and different tumor tissues. GC is usually characterized by abnormal expression of multiple mirnas, so it is of great significance to find specific mirnas for the diagnosis and treatment of GC (10, 11). Abnormal expression of miRNA is related to the occurrence of many tumors, and the maladjustment of miRNA will not only affect the function of intercellular regulatory factors, but also affect tumor growth and invasion (12, 13). Wang (14) showed that miR-4739 is related to tumor progression and plays an inhibitory role in prostate cancer, and down-regulation of its expression can promote the proliferation and migration of prostate cancer cells. Studies on GC have shown that when the malignancy of tumor cells decreases, the expression level of miR-4739 is up-regulated (15). The purpose of this study was to investigate the expression level of miR-4739 in GC, analyze its diagnostic value for GC and the relationship with clinical and pathological characteristics, and analyze its impact on the prognosis of patients.

Materials and Methods

Patients

A total of 96 patients with GC who underwent radical gastrectomy in our hospital from March 2017 to June 2021 were selected. There were 54 males and 42 females, aged from 32 to 78 years, with an average age of (61.34 ± 8.52) years. Tumor node metastasis (TNM) stages included stage I (n = 36), stage II (n = 30), stage III (n = 26) and stage IV (n = 14). Differentiation degree: 58 cases with low differentiation, 22 cases with medium differentiation and 16 cases with high differentiation. Inclusion criteria: All met the diagnostic criteria of GC (16); All patients underwent radical gastrectomy. No radiotherapy or chemotherapy was given before admission; Patients with clear clinical stages and pathologic differentiation. Exclusion criteria: patients with immune system diseases; Patients with malignant tumors in other parts; Long-term use of hormones or non-steroidal anti-inflammatory drugs; Patients with liver and kidney dysfunction, endocrine diseases and blood system diseases; Patients with incomplete clinical data or lost follow-up process. GC tissues of all patients were collected, and normal adjacent tissues (more than 5 cm away from the tumor boundary and confirmed by pathology to have no infiltration of carcinomatous tissues) were collected as controls. All tissue samples were excised, rinsed with PBS, placed in liquid nitrogen for temporary storage, and quickly transferred to −80°C for storage after quick-freezing overnight.

Expression of miR-4739 Detected by Real-Time Quantitative PCR (qRT-PCR)

The total RNA in GC tissues and adjacent tissues was extracted by Trizol method. Detect that molecular weight of the RNA by adopting gel electrophoresis; RNA concentration was detected by spectrophotometer. The RT reaction was performed using ONE STEP PrimeScript cDNA Synthesis Kit (Bao Biological Engineering Dalian Co., LTD) with DNA as the template. The 20 µL PCR reaction system was prepared in an ice bath. The primers were designed according to the data obtained from NCBI database. The primer sequences were as follows: upstream primer of miR-4739: 5′-GCTGGGACATTGAAAGTCTCA-3′; Downstream primer: 5′-GATTTCCCATCGGCGTC-3′. Upstream primer internal reference U6, 5′-CTCGCTTCGGCAGCCACA-3, and downstream primer, 5′-AAGCTTCACGAATTTGCGT-3′. The baseline was adjusted according to the instructions, the threshold was set in the linear part of the log plot of fluorescence values, and the Ct values of the miR-4739 band and the internal reference U6 band were read from the software. Δct = mean sample ct−mean internal reference ct, ΔΔct = Δct- (mean random negative control sample Ct−mean internal reference Ct), and 2−ΔΔCt was used to represent the relative expression level of miR-4739.

Follow-Up

Patients were followed-up by outpatient or telephone every 3 months after operation. The deadline of follow-up was December 2021. The survival time of the patient was set as 1 d from the date of the first operation to the date of her death or the end of her follow-up. According to the survival state of the patients, they were divided into the survival group and the death group.

Statistical Methods

All data were processed with SPSS 22.0 statistical software. The enumeration data were examined by X2 test and expressed by [n(%)], the measurement data were examined by t-test and expressed by . Multivariate analysis adopts multiple Logistic regression model. The ROC curve was used to analyze the diagnostic value of miR-4739 in GC patients. Kaplan-meier survival curve was used to analyze the relationship between Mir-4739 and prognosis of gastric cancer patients, and log-rank test was used for comparison. The difference is statistically significant when P < 0.05.

Results

Expression of miR-4739 in GC Tissue and Paracancerous Tissue

The relative expression level of miR-4739 in the GC tissue was (0.39 ± 0.06), lower than that in the paracancerous tissue (1.18 ± 0.19) (P < 0.05). As shown in Figure 1.
Figure 1

Expression of miR-4739 in GC tissue and paracancerous tissue. Note: Compared with gastric cancer tissue, *P < 0.05.

Expression of miR-4739 in GC tissue and paracancerous tissue. Note: Compared with gastric cancer tissue, *P < 0.05.

Diagnostic Value of miR-4739 Expression Level in GC

The AUC of miR-4739 in the diagnosis of GC was 0.705. When the Youden index was 0.320 and the optimal cutoff value was 0.37, the sensitivity was 95.30% and the specificity was 36.70%. As shown in Table 1 and Figure 2.
Table 1

Diagnostic value of miR-4739 expression level in GC.

Predictive indexesAUC95%CIYouden indexSensitivity (%)Specificity (%)Cut-off value
miR-47390.7020.614–0.7900.32095.30%36.70%0.37
Figure 2

Diagnostic value of miR-4739 expression level in GC.

Diagnostic value of miR-4739 expression level in GC. Diagnostic value of miR-4739 expression level in GC.

Relationship between miR-4739 and Clinical Pathological Characteristics

The cells were divided into high-expression (HE) group (>0.37) and low-expression (LE) group (≤0.37) with the best cutoff value of miR-4739 as the boundary. The expression level of miR-4739 in our patient was related to the differentiation degree, lymph node metastasis, tumor diameter, and TNM stage (P < 0.05). As shown in Table 2.
Table 2

Relationship between miR-4739 expression level and clinical pathological features (n,%).

Clinical pathological features n miR-4739χ2 P
HE group (n = 55)LE group (n = 41)
Age       1.3360.248
 ≥60 years old5227(49.09)25(60.98)    
 <60 years old4428(50.91)16(39.02)    
Gender       0.6490.421
 Man5429(52.73)25(60.98)    
 Woman4226(47.27)16(39.02)    
Degree of differentiation       4.8680.027
 Low differentiation5828(50.91)30(73.17)    
 Moderate to high   differentiation3827(49.09)11(26.83)    
Lymph node metastasis       5.2480.022
 Yes6029(52.73)31(75.61)    
 No3626(47.27)10(24.39)    
Tumor diameter       5.2430.022
 ≥5 cm4118(32.73)23(56.10)    
 <5 cm5537(67.27)18(43.90)    
TNM staging       4.2340.040
 Stages I–II5637(67.27)19(46.34)    
 Stages III–IV4018(32.73)22(53.66)    
Relationship between miR-4739 expression level and clinical pathological features (n,%).

Relationship between miR-4739 Expression Level and Prognosis of Patients with GC

During the follow-up period, 26 of 96 patients died, and the survival rate was 72.92%(26/96). The median survival time was 29 months in the miR-4739 LE group, which was shorter than 39 months in the miR-4739 HE group (P < 0.05). As shown in Figure 3.
Figure 3

Relationship between miR-4739 expression level and prognosis of patients with GC.

Relationship between miR-4739 expression level and prognosis of patients with GC.

Univariate Analysis of Prognosis of Patients with GC

Univariate analysis showed that age, degree of differentiation, lymph node metastasis, tumor diameter, TNM staging, and miR-4739 expression were all related to the prognosis of the patient (P < 0.05). As shown in Table 3.
Table 3

Univariate analysis of prognosis of patients with GC (n,%).

FactornSurvival group (n = 70)Death group (n = 26)χ2 P
Age       5.1360.023
 ≥60 years old5233 (47.14)19 (73.08)    
 <60 years old4437 (52.86) 7 (26.92)    
Gender       0.4050.524
 Man5438 (54.29)16 (61.54)    
 Woman4232 (45.71)10 (38.46)    
Degree of differentiation       6.1760.013
 Low differentiation5837 (52.86)21 (80.77)    
 Moderate to high differentiation3833 (47.14) 5 (19.23)    
Lymph node metastasis       7.4410.006
 Yes6038 (54.29)22 (84.62)    
 No3632 (45.71) 4 (15.38)    
Tumor diameter       5.1670.023
 ≥5 cm4125 (35.71)16 (61.54)    
 <5 cm5545 (64.29)10 (38.46)    
TNM staging       8.2530.004
 Stages I–II5647 (67.14) 9 (34.62)    
 Stages III–IV4023 (32.86)17 (65.38)    
Expression of miR-4739       7.4940.006
 High5546 (65.71) 9 (34.62)    
 Low4124 (34.29)17 (65.38)    
Univariate analysis of prognosis of patients with GC (n,%).

Analysis of Multiple Factors Affecting the Prognosis of Patients with GC

Multivariate analysis showed that differentiation degree, lymph node metastasis, tumor diameter, TNM staging, and miR-4739 expression were all independent factors affecting the prognosis of the patients (P < 0.05). As shown in Table 4 and Table 5.
Table 4

Multi-factor analysis assignment table.

FactorsVariableAssignment
AgeX1<60 = 0, ≥60 = 1
Degree of differentiationX2Medium to high differentiation = 0, low differentiation = 1
Lymph node metastasisX3No = 0, yes = 1
Tumor diameterX4<5 cm = 0, ≥5 cm = 1
TNM stagingX5I–II = 0, III–IV = 1
Expression of miR-4739X6Hig = 0, low = 1
Table 5

Multivariate analysis of prognosis of patients with GC.

VariablesBS.EWaldsPOR95%CI
Age0.3950.2061.9520.2141.5060.791–2.142
Degree of differentiation1.1910.4364.5080.0383.2841.715–6.822
Lymph node metastasis1.2930.5115.1060.0253.7041.992–5.846
Tumor diameter1.3360.6945.7080.0193.8091.278–7.328
TNM staging0.7410.3195.5820.0211.5921.105–2.086
Expression of miR-47390.6630.3126.4280.0091.9051.069–3.158
Multi-factor analysis assignment table. Multivariate analysis of prognosis of patients with GC.

Discussion

At present, GC is generally confirmed by gastroscopy and biopsy of the lesion. Due to the invasive nature of gastroscopy operation, this examination method cannot be popularized as a routine physical examination item at present, so GC is still not able to achieve early detection and treatment (17, 18). For the treatment of GC, surgery, radiotherapy and chemotherapy are often used. Every GC patient has different responses to the same treatment. If we can timely understand the body characteristics of each patient and implement different treatment plans for different patients, namely personalized treatment, GC treatment will be further optimized (19, 20). In recent 20 years, the incidence and prevalence of GC in China have increased to varying degrees, especially the incidence of GC in young and middle-aged people in recent 10 years. With the continuous development of medical technology, the survival period of GC has been prolonged, but the mortality rate of GC patients is still high (21, 22). Therefore, it is very important to find tumor markers with high sensitivity and specificity for the diagnosis of GC. Studies have shown that miRNA has a specific expression spectrum in a variety of tumor tissues, and its overexpression may promote the growth and proliferation of tumor cells to a certain extent, thus promoting tumor progression (23, 24). Some studies have also pointed out that miRNA may play a role in promoting and inhibiting tumorigenesis (25). Abnormal regulation of miRNA is usually accompanied by epigenetic changes in genes, such as gene deletions, mutations and abnormal changes in DNA methylation level. MicroRNAs are a series of small, non-coding single-stranded RNA fragments in the body, which can regulate the translation and degradation of mRNA by ligating clip pairs in the untranslated region at the 3′ end of mRNAs, thereby affecting the proliferation and differentiation of histiocytes (26, 27). With the deepening of research on microRNAs, more and more research results show that in the process of occurrence and development of many tumors, the expression level of microRNAs is often abnormally increased or decreased (28). As a member of microRNAs, studies have found that Mir-4739 can play an inhibitory role in prostate cancer, and down-regulation of its expression can promote the proliferation. In GC, mir-4739 expression level was up-regulated in GC cells with down-regulated oncogene expression level. The results of this study showed that the relative expression level of miR-4739 in GC tissues was (0.39 ± 0.06), lower than that in paracancerous tissues (1.18 ± 0.19). These results indicated that the miR-4739 was closely related to the occurrence of GC. The reason was analyzed as follows: overexpression of miR-4739 inhibited the expression of a variety of cell surface molecules, thus inhibiting the migration of tumor cells. The AUC of miR-4739 in the diagnosis of GC was 0.705. When the Youden Index was 0.320 and the optimal cutoff value was 0.37, the sensitivity was 95.30% and specificity was 36.70%. These results indicated that miR-4739 had certain diagnostic value in patients with GC. Further analysis results in this study showed that abnormal expression of miR-4739 was related to tumor differentiation degree, lymph node metastasis, tumor diameter and TNM stage of patients. Patients with low differentiation degree, lymph node metastasis, large tumor diameter and high TNM stage had low expression level of miR-4739. During the follow-up period, 26 of 96 patients died, and the survival rate was 72.92%(26/96). The median survival time was 29 months in the miR-4739 LE group, which was horter than 39 months in the miR-4739 HE group. In addition, univariate and multivariate analyses showed that differentiation, lymph node metastasis, tumor diameter, TNM stage, and miR-4739 expression were all independent factors affecting the prognosis of the patient. Among them, patients with low differentiation, lymph node metastasis, large tumor diameter, high TNM staging and low expression level of miR-4739 have poor prognosis. All these have indicated that miR-4739 level can predict the prognosis of GC patients. The deficiency of this study is that only the expression of Mir-4739 in GC tissues was detected, and analysis of Mir-4739 may be able to diagnose and predict the prognosis of GC patients. However, the specific mechanism of mir-4739 was not explored in this study, which needs to be further explored in the future.

Conclusion

The expression of miR-4739 in GC tissue was down-regulated, and its level was related to the degree of differentiation, lymph node metastasis, tumor diameter, and TNM stage. The expression level of miR-4739 has certain diagnostic value for patients with GC, and the prognosis of patients in LE group was worse than that in HE group.
  28 in total

Review 1.  Altered MiRNA expression in gastric cancer: a systematic review and meta-analysis.

Authors:  Qi-Xian Wang; You-Qing Zhu; Hu Zhang; Jun Xiao
Journal:  Cell Physiol Biochem       Date:  2015-01-30

Review 2.  Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.

Authors:  Parisa Karimi; Farhad Islami; Sharmila Anandasabapathy; Neal D Freedman; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-11       Impact factor: 4.254

Review 3.  MiRNA as potential biomarkers and therapeutic targets for gastric cancer.

Authors:  Vivian Yvonne Shin; Kent-Man Chu
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 4.  MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell.

Authors:  Narjes Jafari; Saeid Abediankenari
Journal:  Tumour Biol       Date:  2017-05

5.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

Review 6.  Progress in the treatment of advanced gastric cancer.

Authors:  Zheyu Song; Yuanyu Wu; Jiebing Yang; Dingquan Yang; Xuedong Fang
Journal:  Tumour Biol       Date:  2017-07

Review 7.  Gastric Cancer: Recent Molecular Classification Advances, Racial Disparity, and Management Implications.

Authors:  Aravind Sanjeevaiah; Naga Cheedella; Caitlin Hester; Matthew R Porembka
Journal:  J Oncol Pract       Date:  2018-04       Impact factor: 3.840

Review 8.  Diagnosis and management of high risk group for gastric cancer.

Authors:  Hyuk Yoon; Nayoung Kim
Journal:  Gut Liver       Date:  2015-01       Impact factor: 4.519

9.  Serum biomarker panels for the diagnosis of gastric cancer.

Authors:  Dan Wu; Pinglu Zhang; Ji Ma; Jinbo Xu; Li Yang; Weidan Xu; Haifeng Que; Meifen Chen; Hongtao Xu
Journal:  Cancer Med       Date:  2019-03-14       Impact factor: 4.452

Review 10.  A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors.

Authors:  Kuo Yang; Lijie Lu; Huayi Liu; Xiujuan Wang; Ying Gao; Liu Yang; Yupeng Li; Meiling Su; Ming Jin; Samiullah Khan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-11-09       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.